Analysis Tools
normal phenotype
|
• numbers of cells in B subfractions in spleen and bone marrow is unchanged vs wild-type
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• numbers of cells in B subfractions in spleen and bone marrow is unchanged vs wild-type
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 2-fold
|
|
• 8-fold in the peripheral blood
|
|
• 10-fold compared with Cd79atm1(Cre)Reth/Cd79a+ or Tg(IghMyc)22Bri mice
|
|
• 2-fold
|
|
• 8-fold in the peripheral blood
|
|
• 10-fold compared with Cd79atm1(Cre)Reth/Cd79a+ or Tg(IghMyc)22Bri mice
|
|
• 2-fold
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 15-fold
|
|
• 7.5-fold compared with Tg(IghMyc)22Bri mice
|
|
• 60-fold compared with Cd79atm1(Cre)Reth/Cd79a+ or Tg(IghMyc)22Bri mice
|
|
• compared with Tg(IghMyc)22Bri mice
|
|
• compared with Tg(IghMyc)22Bri mice
• however, the range to tumor types is the same
|
|
• 15-fold
|
|
• 15-fold
|
|
• 7.5-fold compared with Tg(IghMyc)22Bri mice
|
|
• 60-fold compared with Cd79atm1(Cre)Reth/Cd79a+ or Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• in pre-B cells and mature B cells (1.5-fold)
|
|
|
• of transitional, marginal zone and follicular B cells
• when B cells are stimulated with anti-IgM or anti-IgM plus anti-CD40
• in B cells stimulated with LPS plus IL4
|
|
|
• partially blocked at pre-B stage
|
|
|
• following stimulation of B cells with LPS or LPS plus IL4
|
|
|
• 3-fold for recirculating mature B cells due to increased apoptosis
• of B220+IgM+ B cells in the spleen
|
|
|
• virtually absent in the peritoneal cavity
|
|
|
• due to increased apoptosis
|
|
|
• mice stimulated with a T-independent antigen, TNP-Ficoll, fail to mount a TNP-specific IgM or IgG3 unlike control mice
• mice stimulated with a T-dependent antigen, NP(15)CGG, produce less NP-specific IgG1 compared with control mice
|
|
|
• 4.5-fold in unstimulated mice
|
|
|
• 2-fold in unstimulated mice
• in mice stimulated with NP(15)CGG
|
|
|
• 32-fold in unstimulated mice
|
|
|
• 37-fold in unstimulated mice
• in mice stimulated with TNP-Ficoll
|
|
|
• 2.5-fold in unstimulated mice
• in mice stimulated with TNP-Ficoll
|
|
|
• mice infected with vesicular stomatitis virus (VSV) exhibit delayed anti-VSV antibody production and reduced anti-VSV IgG levels compared with control mice
|
|
|
• in pre-B cells and mature B cells (1.5-fold)
|
|
|
• of transitional, marginal zone and follicular B cells
• when B cells are stimulated with anti-IgM or anti-IgM plus anti-CD40
• in B cells stimulated with LPS plus IL4
|
|
|
• in pre-B cells and mature B cells (1.5-fold)
|
|
|
• of transitional, marginal zone and follicular B cells
• when B cells are stimulated with anti-IgM or anti-IgM plus anti-CD40
• in B cells stimulated with LPS plus IL4
|
|
|
• partially blocked at pre-B stage
|
|
|
• following stimulation of B cells with LPS or LPS plus IL4
|
|
|
• 3-fold for recirculating mature B cells due to increased apoptosis
• of B220+IgM+ B cells in the spleen
|
|
|
• virtually absent in the peritoneal cavity
|
|
|
• due to increased apoptosis
|
|
|
• 4.5-fold in unstimulated mice
|
|
|
• 2-fold in unstimulated mice
• in mice stimulated with NP(15)CGG
|
|
|
• 32-fold in unstimulated mice
|
|
|
• 37-fold in unstimulated mice
• in mice stimulated with TNP-Ficoll
|
|
|
• 2.5-fold in unstimulated mice
• in mice stimulated with TNP-Ficoll
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 2-fold in pro-B/pre-B
|
|
• 8-fold in the bone marrow
|
|
• 4-fold in the spleen
|
|
• in the bone marrow
|
|
• 2-fold in pro-B/pre-B
|
|
• 8-fold in the bone marrow
|
|
• 4-fold in the spleen
|
|
• in the bone marrow
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• greater than 50-fold
|
|
• compared with Tg(IghMyc)22Bri mice
|
|
• greater than 50-fold
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ lymphocytes and anti-immunoglobulin M (anti-IgM)
|
|
• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ lymphocytes and anti-immunoglobulin M (anti-IgM)
|
|
• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ lymphocytes and anti-immunoglobulin M (anti-IgM)
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• greater survival of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)
|
|
• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)
|
|
• greater survival of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)
|
|
• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)
|
| N |
• normal T cell and B cell development and homeostasis
|
|
• greater survival of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)
|
|
• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice have a less than 40% survival rate at 1 year
|
|
• IgG deposition in kidney glomeruli is seen at 20 weeks of age
|
|
• mice show autoantibodies that are specifically seen in lupus; ssDNA, dsDNA, dsRNA and chromatin
|
|
• anti-nuclear antibodies in the sera in 20-week old mice
|
|
• mice exhibit chromatin autoantibodies at 8 weeks of age and at 20 weeks of age, mice show chromatin antibodies at amounts comparable to those seen in NZB/NZW mice
|
|
• IgG deposition in kidney glomeruli is seen at 20 weeks of age
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| systemic lupus erythematosus | DOID:9074 |
OMIM:152700 OMIM:300809 OMIM:605480 OMIM:608437 OMIM:609903 OMIM:609939 OMIM:610065 OMIM:610066 OMIM:612254 OMIM:612378 OMIM:613145 OMIM:614420 |
J:178833 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in the lymph nodes
|
|
• in the spleen and blood
|
|
• in the spleen
|
|
• in the spleen
|
|
• B cells and marginal zone B cells exhibit increased chemotactic response to S1P compared with control cells
• long-term accumulation of B cells in the lymph node is reduced compared with control cells
• marginal zone B cells exhibit decreased chemotactic response to CCL21 compared with control cells
• marginal zone B cells exhibit increased chemotactic response to SEW2871 (S1PR1-selective agonist) compared with control cells
• marginal zone B cell relocalization to the follicle induced by FTY720 treatment is delayed compared to in control mice
• splenic follicular dendritic cells exhibit reduced deposition of phycoerythrin-induced complexes compared with control cells
• however, transfer into a S1P null mouse restores normal lymph node accumulation
|
|
• in the lymph nodes
|
|
• in the spleen and blood
|
|
• in the spleen
|
|
• in the spleen
|
|
• B cells and marginal zone B cells exhibit increased chemotactic response to S1P compared with control cells
• long-term accumulation of B cells in the lymph node is reduced compared with control cells
• marginal zone B cells exhibit decreased chemotactic response to CCL21 compared with control cells
• marginal zone B cells exhibit increased chemotactic response to SEW2871 (S1PR1-selective agonist) compared with control cells
• marginal zone B cell relocalization to the follicle induced by FTY720 treatment is delayed compared to in control mice
• splenic follicular dendritic cells exhibit reduced deposition of phycoerythrin-induced complexes compared with control cells
• however, transfer into a S1P null mouse restores normal lymph node accumulation
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection
|
|
• increase in frequency of plasma cells in the B cell population (4.96% of B cells compared to 0.04% in controls)
|
|
• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection
|
|
• cell surface mIgM and mIgD are reduced 50% in B cells and B cells express reduced CD93, CD95, and CD80 indicating a loss of anergic B cells
• B cells lose features of anergy, including antigen unresponsiveness measured by BCR aggregation-induced Akt activation and calcium mobilization
• increase in frequency of B cells with activated phenotype (CD86+)
|
|
• mice spontaneously express about 4-fold increased autoantibody by 20 weeks of age
|
|
• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection
|
|
• increase in frequency of plasma cells in the B cell population (4.96% of B cells compared to 0.04% in controls)
|
|
• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• three fold fewer pro-B cells
|
|
• three fold fewer pro-B cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• strong reduction in number of B cell precursors is seen in bone marrow
|
|
• drastic reductions in B cell number are found in spleen, thymus, and bone marrow
|
|
• drastic reduction in pre-B cells indicates that Sfrs3 is required for pre-B cell survival
|
|
• strong reduction in number of B cell precursors is seen in bone marrow
|
|
• drastic reductions in B cell number are found in spleen, thymus, and bone marrow
|
|
• drastic reduction in pre-B cells indicates that Sfrs3 is required for pre-B cell survival
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• there is a complete block pro-B cell differentation at the BP-1+HASlow stage
|
|
• there is a complete block pro-B cell differentation at the BP-1+HASlow stage
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in the spleen but not as severe as in Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• in the bone marrow but not as severe as in Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• in the spleen but not as severe as in Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• in the bone marrow but not as severe as in Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• of pre BII cells and large pre BII cells
|
|
• numbers of pre BI cells are reduced by 60%-80%
|
|
• block in B cell differentiation as early as the pre BI cell stage
only 4.5% of pre B cells are in S phase compared to 80% for wild-type cells
|
|
• only a very few B cells remain
|
|
• spleen is virtually empty of circulating mature B cells
• in bone marrow, only a very few B cells remain
|
|
• fewer than 1% of pre BII cell stage cells remain
|
|
• virtually empty of circulating mature B cells
|
|
• of pre BII cells and large pre BII cells
|
|
• numbers of pre BI cells are reduced by 60%-80%
|
|
• block in B cell differentiation as early as the pre BI cell stage
only 4.5% of pre B cells are in S phase compared to 80% for wild-type cells
|
|
• spleen is virtually empty of circulating mature B cells
• in bone marrow, only a very few B cells remain
|
|
• fewer than 1% of pre BII cell stage cells remain
|
|
• virtually empty of circulating mature B cells
|
|
• of pre BII cells and large pre BII cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 3 hours after antigen injection, B cells fail to accumulate in the outer follicle instead had already arrived at the B-T boundary unlike in control cells
• however, B cells are distributed at the B-T boundary after 6 hours
|
|
• 3 hours after antigen injection, B cells fail to accumulate in the outer follicle instead had already arrived at the B-T boundary unlike in control cells
• however, B cells are distributed at the B-T boundary after 6 hours
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• two fold more pro-B cells than in controls
• proliferation of c-Kithi pro-B cells is normal
• c-Kitlo pro-B cells accumulate in the G1-G0 phases of the cell cycle
• cells are smaller with functionally rearranged immunoglobulin mu
• c-Kithi pro-B cells expressing immunoglobulin mu are increased
|
|
• six fold reduction in total B cell number in bone marrow relative to controls
|
|
• nearly complete loss of pre-B cells
|
|
• two fold more pro-B cells than in controls
• proliferation of c-Kithi pro-B cells is normal
• c-Kitlo pro-B cells accumulate in the G1-G0 phases of the cell cycle
• cells are smaller with functionally rearranged immunoglobulin mu
• c-Kithi pro-B cells expressing immunoglobulin mu are increased
|
|
• six fold reduction in total B cell number in bone marrow relative to controls
|
|
• nearly complete loss of pre-B cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice exhibit normal splenic B cells numbers and early stages of B cell differentiation
|
|
• delayed entry into S phase on activation of resting, affecting follicular more than marginal zone B cells
|
|
• in response to LPS or anti-CD40 stimulation
|
|
• reduced immunoglobin class switching in splenic B cells
|
|
• delayed entry into S phase on activation of resting, affecting follicular more than marginal zone B cells
|
|
• in response to LPS or anti-CD40 stimulation
|
|
• reduced immunoglobin class switching in splenic B cells
|
|
• delayed entry into S phase on activation of resting, affecting follicular more than marginal zone B cells
|
|
• in response to LPS or anti-CD40 stimulation
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
N |
• bone marrow B cell development and stimulated and unstimulated splenic B cell proliferation are restored compared to in Cd79atm1(cre)Reth/Cd79a+ Huwe1tm1.1Mak/Y mice
|
|
|
• to a greater extent than in Cd79atm1(cre)Reth/Cd79a+ Huwe1tm1.1Mak/Y mice following stimulation of B cells with LPS or LPS plus IL4
|
|
|
• virtually absent in the peritoneal cavity
|
|
|
• to a greater extent than in Cd79atm1(cre)Reth/Cd79a+ Huwe1tm1.1Mak/Y mice following stimulation of B cells with LPS or LPS plus IL4
|
|
|
• virtually absent in the peritoneal cavity
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• decrease in B cell progenitors
|
|
• decrease in the number of CD19+ B cells in the spleen
|
|
• decrease in B cell progenitors
|
|
• decrease in the number of CD19+ B cells in the spleen
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• while B cell numbers are increased relative to in Cd79atm1(cre)Reth/Cd79a+ Bcl2l11tm1.1Ast/Bcl2l11+ Dicer1tm1Mmk/Dicer1tm1Mmk mice, numbers are still lower than in wild-type mice
|
|
• while B cell numbers are increased relative to in Cd79atm1(cre)Reth/Cd79a+ Bcl2l11tm1.1Ast/Bcl2l11+ Dicer1tm1Mmk/Dicer1tm1Mmk mice, numbers are still lower than in wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• B cell development is rescued compared with Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with control and Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with control and Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with control and Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with control and Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with control and Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with control and Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with control and Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
• compared with control and Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+ mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• accelerated antigen-specific B cell response in vivo in response to ovalbumin
|
|
• increased anti-ovalbumin IgG titer after ovalbumin treatment
• CpG-DNA-treated mice exhibit renal IgG deposits unlike wild-type mice
|
|
• in ovalbumin-treated mice
|
|
• CpG-DNA-treated mice exhibit increased anti-double stranded DNA antibody levels and renal IgG deposits compared with control mice
|
|
• in CpG-DNA-treated mice
• however, untreated mice do not produce autoantibodies
|
|
• accelerated antigen-specific B cell response in vivo in response to ovalbumin
|
|
• increased anti-ovalbumin IgG titer after ovalbumin treatment
• CpG-DNA-treated mice exhibit renal IgG deposits unlike wild-type mice
|
|
• in ovalbumin-treated mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• increased percentage of B220+ CD43+ pro-B cells in bone marrow
|
|
• increased percentage of B220+ CD19+ muHC- CD25- late pro-B cells in bone marrow
|
|
• decrease in CD19+ B cells in splenic B cell compartment
• reduced frequency of peritoneal B cells
• reduced percentage of B220hi CD43- recirculating B cells in bone marrow
• reduced percentage of B220int CD43- pre-B cells in bone marrow
• reduced number of muHC+ cells in IL7+ bone marrow B cell cultures
• normal frequency of cells with intracellular muHC in IL7+ bone marrow B cell cultures
|
|
• reduced CD25+ pre-B cell number in bone marrow
|
|
• increased percentage of B220+ CD43+ pro-B cells in bone marrow
|
|
• increased percentage of B220+ CD19+ muHC- CD25- late pro-B cells in bone marrow
|
|
• decrease in CD19+ B cells in splenic B cell compartment
• reduced frequency of peritoneal B cells
• reduced percentage of B220hi CD43- recirculating B cells in bone marrow
• reduced percentage of B220int CD43- pre-B cells in bone marrow
• reduced number of muHC+ cells in IL7+ bone marrow B cell cultures
• normal frequency of cells with intracellular muHC in IL7+ bone marrow B cell cultures
|
|
• reduced CD25+ pre-B cell number in bone marrow
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 2.5-fold reduction in frequency of muHC+ lambda5+ cells in bone marrow
• increase in lambda5+ only bone marrow cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mutants exhibit an increase in percentage and the total number of germinal center B cells compared to wild-type mice, although the total number of germinal center B cells is lower than in Fcgr2b homozygotes (that are also heterozygous for the floxed Traf3ip2 allele)
|
|
• develop glomerulonephritis comparable to single Fcgr2b homozygotes
|
|
• mutants exhibit an increase in percentage and the total number of germinal center B cells compared to wild-type mice, although the total number of germinal center B cells is lower than in Fcgr2b homozygotes (that are also heterozygous for the floxed Traf3ip2 allele)
|
|
• develop glomerulonephritis comparable to single Fcgr2b homozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• there is complete block of B cell development in spleen and bone marrow
|
|
• proportion of CD19+ lymphocytes is 10% compared to 74% in wild-type
|
|
• there is complete block of B cell development in spleen and bone marrow
|
|
• proportion of CD19+ lymphocytes is 10% compared to 74% in wild-type
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice exhibit normal formation of precursor and mature B cell populations
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• B cell development is blocked at pro-B cell stage
|
|
• in the spleen, inguinal lymph nodes, and peritoneal cavity
|
|
• B cell development is blocked at pro-B cell stage
|
|
• slightly
|
|
• in the spleen, inguinal lymph nodes, and peritoneal cavity
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice exhibit normal splenic CD4+ and CD8+ T cells
|
|
• total block at the pro-B cell to pre-B cell transition
|
|
• severe
|
|
• hyposplenia
|
|
• absent
|
|
• absent
|
|
• total block at the pro-B cell to pre-B cell transition
|
|
• severe
|
|
• hyposplenia
|
|
• absent
|
|
• absent
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 97% of B lineage cells are EYFP-positive compared with 33% in Cd19tm1(cre)Cgn-expressing mice indicating more efficient loxP recombination in developing B cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• while B cell numbers are increased relative to in Cd79atm1(cre)Reth/Cd79a+ Dicer1tm1Mmk/Dicer1tm1Mmk mice, numbers are still lower than in wild-type mice
|
|
• while B cell numbers are increased relative to in Cd79atm1(cre)Reth/Cd79a+ Dicer1tm1Mmk/Dicer1tm1Mmk mice, numbers are still lower than in wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• stimulated B cells exhibit reduced ability to induced T cell proliferation
|
|
• from stimulated B cells
|
|
• stimulated B cells exhibit reduced ability to induced T cell proliferation
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in the spleen
|
|
• 5- to 10-fold in peritoneal washes
|
|
• B cells exhibit reduced alpha-IgM-mediated calcium flux compared with control cells
|
|
• alpha-IgM-mediated
|
|
• following BCR-induction
• mild defects in alpha-IgM-mediated proliferation
|
|
• to IgG3 induced by T cell-independent type II antigens
|
|
• marginal zone B cells exhibit decreased TNP-Ficoll binding compared with wild-type cells
|
|
• in the spleen
|
|
• 5- to 10-fold in peritoneal washes
|
|
• B cells exhibit reduced alpha-IgM-mediated calcium flux compared with control cells
|
|
• alpha-IgM-mediated
|
|
• following BCR-induction
• mild defects in alpha-IgM-mediated proliferation
|
|
• to IgG3 induced by T cell-independent type II antigens
|
|
• marginal zone B cells exhibit decreased TNP-Ficoll binding compared with wild-type cells
|
|
• alpha-IgM-mediated
|
|
• following BCR-induction
• mild defects in alpha-IgM-mediated proliferation
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• usage of Dh elements and N nucleotide insertion into Igkappa is increased compared to in wild-type mice
|
|
• usage of Dh elements and N nucleotide insertion into Igkappa is increased compared to in wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• hardly detected
|
|
• in the bone marrow
|
|
• B cell development is almost completely blocked at the pro- to pre-B cell transition
|
|
• hardly detected
|
|
• in the bone marrow due to a massive increase in apoptosis
|
|
• hardly detected
|
|
• in the bone marrow
|
|
• B cell development is almost completely blocked at the pro- to pre-B cell transition
|
|
• hardly detected
|
|
• in the bone marrow due to a massive increase in apoptosis
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in an adoptive transfer experiment, B cells are at a competitive disadvantage to wild-type B cells
|
|
• IgM-secreting plasma cells
|
|
• in peripheral blood
|
|
• mice exhibit a reduction in recirculating, mature (IgM+B220hi fraction F) B cells in the bone marrow compared with Grb2tm1Lnit homozygote controls
• the number of mature B cells in the spleen is half that in wild-type mice
• however, mice exhibit normal numbers of marginal zone B cells and B1 cells in the spleen and peritoneal cavity
|
|
• in mice immunized with sheep red blood cell
|
|
• in mice immunized with sheep red blood cell
|
|
• mice exhibit reduced Brd-U labeled T1/marginal zone B cells compared with cells from Grb2tm1Lnit homozygote controls
• however, bone marrow pre-B and immature B cell proliferation is normal
|
|
• immature and mature B cells exhibit a slight increase in spontaneous apoptosis compared to in Grb2tm1Lnit homozygote controls
|
|
• after anti-IgM or LPS stimulation
|
|
• in response to secondary exposure to human cytomegalovirus-derived virus-like particles
• however, primary IgG response is normal
|
|
• in TNP-ficoll treated mice
|
|
• 10-fold in unstimulated mice
• however, IgM response to TNP-ficoll is normal
|
|
• mice exhibit impaired memory response to human cytomegalovirus-derived virus-like particles compared with Grb2tm1Lnit homozygote controls
|
|
• in an adoptive transfer experiment, B cells are at a competitive disadvantage to wild-type B cells
|
|
• IgM-secreting plasma cells
|
|
• in peripheral blood
|
|
• mice exhibit a reduction in recirculating, mature (IgM+B220hi fraction F) B cells in the bone marrow compared with Grb2tm1Lnit homozygote controls
• the number of mature B cells in the spleen is half that in wild-type mice
• however, mice exhibit normal numbers of marginal zone B cells and B1 cells in the spleen and peritoneal cavity
|
|
• in mice immunized with sheep red blood cell
|
|
• in mice immunized with sheep red blood cell
|
|
• mice exhibit reduced Brd-U labeled T1/marginal zone B cells compared with cells from Grb2tm1Lnit homozygote controls
• however, bone marrow pre-B and immature B cell proliferation is normal
|
|
• immature and mature B cells exhibit a slight increase in spontaneous apoptosis compared to in Grb2tm1Lnit homozygote controls
|
|
• after anti-IgM or LPS stimulation
|
|
• in response to secondary exposure to human cytomegalovirus-derived virus-like particles
• however, primary IgG response is normal
|
|
• in TNP-ficoll treated mice
|
|
• 10-fold in unstimulated mice
• however, IgM response to TNP-ficoll is normal
|
|
• mice exhibit impaired memory response to human cytomegalovirus-derived virus-like particles compared with Grb2tm1Lnit homozygote controls
|
|
• immature and mature B cells exhibit a slight increase in spontaneous apoptosis compared to in Grb2tm1Lnit homozygote controls
|
|
• after anti-IgM or LPS stimulation
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop acute leukemia with an incidence of 53% at 12 months of age
• leukemia cells are present in the bone marrow, spleen, lymph nodes and infiltrate multiple organs, including the CNS
• 94% of leukemias have a B cell precursor phenotype
|
|
• in leukemic mice
|
|
• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation
|
|
• in leukemic mice
|
|
• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice
|
|
• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice
|
|
• leukemic mice present with leukocytosis
|
|
• in leukemic mice
|
|
• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation
|
|
• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice
|
|
• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice
|
|
• leukemic mice present with leukocytosis
|
|
• in leukemic mice
|
|
• in leukemic mice
|
|
• in leukemic mice
|
|
• in leukemic mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| acute lymphoblastic leukemia | DOID:9952 |
OMIM:247640 OMIM:613065 |
J:226241 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• there is a pronounced block in B cell development at transition stage 1 in the spleen
|
|
|
• mice show dramatic reduction in peripheral B cell numbers
|
|
|
• numbers of mature B cells are reduced to 10% of levels in controls
|
|
|
• there is a pronounced block in B cell development at transition stage 1 in the spleen
|
|
|
• mice show dramatic reduction in peripheral B cell numbers
|
|
|
• numbers of mature B cells are reduced to 10% of levels in controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• slightly less in LPS-stimulated marginal zone
• however, proliferation of alphaIgM-stimulated follicular B cells is not significantly different from that of wild-type cells
|
|
• FO I B cells
|
|
• total and FO II B cells
|
|
• slightly less in LPS-stimulated marginal zone
• however, proliferation of alphaIgM-stimulated follicular B cells is not significantly different from that of wild-type cells
|
|
• FO I B cells
|
|
• total and FO II B cells
|
|
• slightly less in LPS-stimulated marginal zone
• however, proliferation of alphaIgM-stimulated follicular B cells is not significantly different from that of wild-type cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Small spleen size in Atmintm1.2Jhh/Atmintm1.2Jhh/ Cd79atm1(cre)Reth/Cd79a+ mice
|
• impaired in a cell-intrinsic manner
• not rescued by provision of a prearranged BCR
|
|
• more than 7-fold in the bone marrow
|
|
• more than 7-fold in the spleen
|
|
• 3-fold in the bone marrow
|
|
• 2-fold
|
|
• immature and transitional B cells exhibit a 3-fold increase in cell death compared with control cells
|
|
• impaired in a cell-intrinsic manner
• not rescued by provision of a prearranged BCR
|
|
• more than 7-fold in the bone marrow
|
|
• more than 7-fold in the spleen
|
|
• 3-fold in the bone marrow
|
|
• 2-fold
|
|
• immature and transitional B cells exhibit a 3-fold increase in cell death compared with control cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• in the spleen and lymph nodes
|
|
|
• increase in the proportion of CD19+ CD138hi plasma cells
|
|
|
• B cell lymphopenia
|
|
|
• decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells
• decrease in the proportion and number of CD19+ B cells in the spleen
|
|
|
• decrease in absolute number but not the proportion of follicular B cells
|
|
|
• decrease in the percentage and absolute number of marginal zone B cells
• the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent
|
|
|
• virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses
• abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus
|
|
|
• elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine
|
|
|
• modest degree of glomerular damage
|
|
|
• in the spleen and lymph nodes
|
|
|
• increase in the proportion of CD19+ CD138hi plasma cells
|
|
|
• B cell lymphopenia
|
|
|
• decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells
• decrease in the proportion and number of CD19+ B cells in the spleen
|
|
|
• decrease in absolute number but not the proportion of follicular B cells
|
|
|
• decrease in the percentage and absolute number of marginal zone B cells
• the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent
|
|
|
• virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses
• abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus
|
|
|
• elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• B cells exhibit less calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice
|
|
• anti-IgM-treated B cells exhibit decreased proliferation unlike control cells
• however, B cell proliferation stimulated by anti-CD40 or LPS is normal
|
|
• following PMA and ionomycin stimulation
|
|
• B cells exhibit less calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice
|
|
• anti-IgM-treated B cells exhibit decreased proliferation unlike control cells
• however, B cell proliferation stimulated by anti-CD40 or LPS is normal
|
|
• anti-IgM-treated B cells exhibit decreased proliferation unlike control cells
• however, B cell proliferation stimulated by anti-CD40 or LPS is normal
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice exhibit normal B cell development
|
|
• following immunization with MOG35-55
|
|
• following immunization with MOG35-55
|
|
• following immunization with MOG35-55
|
|
• B cells exhibit little calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice
• B cells treated with anti-IgM, anti-IgM and IL4, or anti-IgM and anti-CD40 exhibit reduced survival compared with control cells
• however, B cell treated with anti-CD40 or LPS exhibit normal survival and B cell antibody response is normal
|
|
• B cells treated anti-IgM fail to exhibit proliferation unlike control cells
• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells
• however, B cell proliferation stimulated by anti-CD40 or LPS is normal
|
|
• in splenocytes following immunization with MOG35-55
|
|
• following stimulation with PMA and ionomycin, LPS, anti-IgM and anti-CD40, or anti-IgM and LPS
|
|
• in splenocytes following immunization with MOG35-55
|
|
• in splenocytes following immunization with MOG35-55
|
|
• following immunization with MOG35-55, mice exhibit increased inflammatory cells infiltration (CD8+ and CD4+ T cells, T regulatory cells), demyelination, and cytokine production (IFN-gamma, IL17, and IL10) compared with control mice
|
|
• following immunization with MOG35-55
|
|
• following immunization with MOG35-55
|
|
• following immunization with MOG35-55
|
|
• following immunization with MOG35-55
|
|
• B cells exhibit little calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice
• B cells treated with anti-IgM, anti-IgM and IL4, or anti-IgM and anti-CD40 exhibit reduced survival compared with control cells
• however, B cell treated with anti-CD40 or LPS exhibit normal survival and B cell antibody response is normal
|
|
• B cells treated anti-IgM fail to exhibit proliferation unlike control cells
• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells
• however, B cell proliferation stimulated by anti-CD40 or LPS is normal
|
|
• B cells treated anti-IgM fail to exhibit proliferation unlike control cells
• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells
• however, B cell proliferation stimulated by anti-CD40 or LPS is normal
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• B cell proliferation in response to anti-IgM, anti-CD40, and LPS is normal
|
|
• B cells exhibit a mild decrease in calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice
|
|
• B cells exhibit a mild decrease in calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• increased proliferation in cells lacking expression of Was compared to cells expressing Was in the follicular and germinal center B cell populations
|
|
|
• while B cell numbers are similar to controls, the distribution of cells lacking expression of Was is biased against marginal zone B cells
• enrichment of null cells in the germinal center cell and plasma cell populations
|
|
|
• increased proliferation in cells lacking expression of Was compared to cells expressing Was in the follicular and germinal center B cell populations
|
|
|
• while B cell numbers are similar to controls, the distribution of cells lacking expression of Was is biased against marginal zone B cells
• enrichment of null cells in the germinal center cell and plasma cell populations
|
|
|
• increased proliferation in cells lacking expression of Was compared to cells expressing Was in the follicular and germinal center B cell populations
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• in the spleen and lymph nodes
|
|
|
• increase in the proportion of CD19+ CD138hi plasma cells
|
|
|
• B cell lymphopenia
|
|
|
• decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells
• decrease in the proportion and number of CD19+ B cells in the spleen
|
|
|
• decrease in absolute number but not the proportion of follicular B cells
|
|
|
• decrease in the percentage and absolute number of marginal zone B cells
• the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent
|
|
|
• virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses
• abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus
|
|
|
• elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine
|
|
|
• modest degree of glomerular damage
|
|
|
• in the spleen and lymph nodes
|
|
|
• increase in the proportion of CD19+ CD138hi plasma cells
|
|
|
• B cell lymphopenia
|
|
|
• decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells
• decrease in the proportion and number of CD19+ B cells in the spleen
|
|
|
• decrease in absolute number but not the proportion of follicular B cells
|
|
|
• decrease in the percentage and absolute number of marginal zone B cells
• the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent
|
|
|
• virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses
• abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus
|
|
|
• elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• addition of a pre-rearranged IgH transgene partially but significantly increases the number of CD19+ B cells
|
|
• addition of a pre-rearranged IgH transgene partially but significantly increases the number of CD19+ B cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• memory B cells from mice immunized with NP-CG fail to undergo somatic hypermutation compared with wild-type mice
|
|
• in mice immunized with NP-CG at day 5 and 7 (200-fold)
|
|
• early germinal center memory B cells from mice immunized with NP-CG exhibit a resting state compared with wild-type mice
• however, the number of memory B cells is normal
|
|
• 40 days after immunization with NP-CG, GC-independent memory B cells arise from dividing precursors, fail to exhibit a decrease in proliferation unlike wild-type cells and enter the memory compartment before germinal B cell progeny
|
|
• memory B cells from mice treated with NP-CG produce low affinity antibodies in an IgG1 secondary response unlike wild-type cells
|
|
• memory B cells from mice immunized with NP-CG fail to undergo somatic hypermutation compared with wild-type mice
|
|
• in mice immunized with NP-CG at day 5 and 7 (200-fold)
|
|
• early germinal center memory B cells from mice immunized with NP-CG exhibit a resting state compared with wild-type mice
• however, the number of memory B cells is normal
|
|
• 40 days after immunization with NP-CG, GC-independent memory B cells arise from dividing precursors, fail to exhibit a decrease in proliferation unlike wild-type cells and enter the memory compartment before germinal B cell progeny
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice immunized with NP-CG exhibit normal development of memory B cells
|
|
• in mice immunized with NP-CG
|
|
• in mice immunized with NP-CG
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• defect in RAG-mediated recombination
|
|
• significant reduction in the diversity of IgH chain repetoires
|
|
• decreased absolute numbers of BP1- CD24+ early pro-B cells
|
|
• decreased absolute numbers of BP1+ CD24high late pro-B cells
|
|
• increase in frequency and absolute number of BP1- CD24- pre-pro-B cells
• no increase in proliferation of pre-pro-B cells
|
|
• approximately sixfold decrease in both percentage and total number of B220+ B cells in the bone marrow
• percentages and absolute numbers of B220+ CD43- late-stage B cells and B220high CD43- recirculating B cells are decreased
• severe B lymphopenia in the periphery
|
|
• drastically reduced B220+ CD43+ IgM+ IgD- immature B cell numbers
|
|
• dramatic reduction in the number of B220+ splenic B cells
• IgD+ mature B cells are virtually absent in the spleen
|
|
• drastically reduced B220+ CD43- IgM- IgD- small pre-B cell numbers
|
|
• defect in IgH chain gene expression in pre-pro-B cells
|
|
• defect in RAG-mediated recombination
|
|
• significant reduction in the diversity of IgH chain repetoires
|
|
• decreased absolute numbers of BP1- CD24+ early pro-B cells
|
|
• decreased absolute numbers of BP1+ CD24high late pro-B cells
|
|
• increase in frequency and absolute number of BP1- CD24- pre-pro-B cells
• no increase in proliferation of pre-pro-B cells
|
|
• approximately sixfold decrease in both percentage and total number of B220+ B cells in the bone marrow
• percentages and absolute numbers of B220+ CD43- late-stage B cells and B220high CD43- recirculating B cells are decreased
• severe B lymphopenia in the periphery
|
|
• drastically reduced B220+ CD43+ IgM+ IgD- immature B cell numbers
|
|
• dramatic reduction in the number of B220+ splenic B cells
• IgD+ mature B cells are virtually absent in the spleen
|
|
• drastically reduced B220+ CD43- IgM- IgD- small pre-B cell numbers
|
|
• defect in IgH chain gene expression in pre-pro-B cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• while B cell numbers are increased relative to in Cd79atm1(cre)Reth/Cd79a+ Dicer1tm1Mmk/Dicer1tm1Mmk mice, numbers are still lower than in wild-type mice
|
|
• while B cell numbers are increased relative to in Cd79atm1(cre)Reth/Cd79a+ Dicer1tm1Mmk/Dicer1tm1Mmk mice, numbers are still lower than in wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice exhibit normal conventional B cell development and I cell populations
|
|
• severely impaired B1 B cell development in the peritoneal cavity
|
|
• in the peritoneal cavity
|
|
• in the peritoneal cavity
|
|
• impaired antibody responses to both T cell-dependent and T cell-independent type 2 antigens
|
|
• in unimmunized mice
|
|
• in unimmunized mice
• in mice immunized with NP-CGG
|
|
• in unimmunized mice
|
|
• in unimmunized mice
|
|
• in unimmunized mice
• in mice immunized with NP-Ficoll
|
|
• in unimmunized mice
• in mice immunized with NP-CGG or NP-Ficoll
|
|
• severely impaired B1 B cell development in the peritoneal cavity
|
|
• in the peritoneal cavity
|
|
• in the peritoneal cavity
|
|
• in unimmunized mice
|
|
• in unimmunized mice
• in mice immunized with NP-CGG
|
|
• in unimmunized mice
|
|
• in unimmunized mice
|
|
• in unimmunized mice
• in mice immunized with NP-Ficoll
|
|
• in unimmunized mice
• in mice immunized with NP-CGG or NP-Ficoll
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice exhibit normal size of developing B cell subsets and serum levels of IgG3 and IgA in unimmunized mice
|
|
• in the bone marrow, blood, and spleen
|
|
• in the bone marrow, blood, and spleen
|
|
• decreased after immunization with NP-CGG compared with controls
|
|
• less defined boundaries
|
|
• after immunization with NP-CGG compared with controls
|
|
• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC
• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells
• however, response to S1P is normal as is lymph node egression
|
|
• in unimmunized mice and after immunization with NP-CGG compared with controls
|
|
• in unimmunized mice
|
|
• in unimmunized mice
|
|
• in unimmunized mice and after immunization with NP-CGG compared with controls
|
|
• in the bone marrow, blood, and spleen
|
|
• in the bone marrow, blood, and spleen
|
|
• decreased after immunization with NP-CGG compared with controls
|
|
• less defined boundaries
|
|
• after immunization with NP-CGG compared with controls
|
|
• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC
• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells
• however, response to S1P is normal as is lymph node egression
|
|
• in unimmunized mice and after immunization with NP-CGG compared with controls
|
|
• in unimmunized mice
|
|
• in unimmunized mice
|
|
• in unimmunized mice and after immunization with NP-CGG compared with controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice exhibit normal size of developing B cell subsets and serum levels of IgA in unimmunized mice
|
|
• in the bone marrow, blood, and spleen
|
|
• in the bone marrow, blood, and spleen
|
|
• decreased after immunization with NP-CGG compared with controls
|
|
• less defined boundaries
|
|
• after immunization with NP-CGG compared with controls
|
|
• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC
• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells
• however, response to S1P is normal as is lymph node egression
|
|
• in unimmunized mice and after immunization with NP-CGG compared with controls
|
|
• in unimmunized mice
|
|
• in unimmunized mice
|
|
• in unimmunized mice
|
|
• after immunization with NP-CGG compared with controls
• however, unimmunized mice exhibit normal levels of IgM
|
|
• in the bone marrow, blood, and spleen
|
|
• in the bone marrow, blood, and spleen
|
|
• decreased after immunization with NP-CGG compared with controls
|
|
• less defined boundaries
|
|
• after immunization with NP-CGG compared with controls
|
|
• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC
• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells
• however, response to S1P is normal as is lymph node egression
|
|
• in unimmunized mice and after immunization with NP-CGG compared with controls
|
|
• in unimmunized mice
|
|
• in unimmunized mice
|
|
• in unimmunized mice
|
|
• after immunization with NP-CGG compared with controls
• however, unimmunized mice exhibit normal levels of IgM
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
N |
• no gross development arrest in bone marrow
|
|
|
• recirculating B cells reduced about 20%
|
|
|
• reduced about 20%
|
|
|
• reduced about 20% in the spleen
|
|
|
• reduced about 20% in the spleen
|
|
|
• peritoneal B-1a B cells are reduced about 8 fold
|
|
|
• reduced about 20% in the spleen
|
|
|
• antigen specific B cells fail to increase due to T cell independent type II antibody response
• B cell proliferation after anti-IgM stimulation is severely reduced
|
|
|
• T cell independent type II antibody responses are considerably reduced
|
|
|
• recirculating B cells reduced about 20%
|
|
|
• reduced about 20%
|
|
|
• reduced about 20% in the spleen
|
|
|
• reduced about 20% in the spleen
|
|
|
• peritoneal B-1a B cells are reduced about 8 fold
|
|
|
• reduced about 20% in the spleen
|
|
|
• antigen specific B cells fail to increase due to T cell independent type II antibody response
• B cell proliferation after anti-IgM stimulation is severely reduced
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
N |
• T cell independent type II antibody responses are restored
|
|
|
• B-1a cell development continues to be defective
|
|
|
• B-1a cell development continues to be defective
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at the pre-pro-B cell stage, not rescued by over-expression of Bcl2
|
|
• at the pre-pro-B cell stage, not rescued by over-expression of Bcl2
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/09/2024 MGI 6.23 |
|
|
|
||